Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

0.6183 -0.0117 (-1.86%)
Streaming Delayed Price Updated: 9:34 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,364
Open 0.5900
Bid (Size) 0.5900 (300)
Ask (Size) 0.6400 (100)
Prev. Close 0.6300
Today's Range 0.5900 - 0.6183
52wk Range 0.5601 - 6.290
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update
Company to Focus on Pancreatic Cancer Detection Business in the U.S., Strategic Asset Sales and Future Strategic Transaction 
From Mainz BioMed NV
Via GlobeNewswire

Performance

YTD
-46.7%
-46.7%
1 Month
-43.8%
-43.8%
3 Month
-41.7%
-41.7%
6 Month
-64.9%
-64.9%
1 Year
-88.2%
-88.2%

More News

Read More
News headline image
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Provides Review of 2025 Highlights
From Mainz BioMed NV
Via GlobeNewswire
News headline image
2 Small-Cap Biotechs That Could Reward Patient Investors ↗
Via MarketBeat
News headline image
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Attend 2025 Maxim Growth Summit
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
From Mainz BioMed NV
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
From Mainz BioMed NV
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
From Mainz BioMed NV
Via GlobeNewswire

Frequently Asked Questions

Is Mainz Biomed N.V. - Ordinary Shares publicly traded?
Yes, Mainz Biomed N.V. - Ordinary Shares is publicly traded.
What exchange does Mainz Biomed N.V. - Ordinary Shares trade on?
Mainz Biomed N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Mainz Biomed N.V. - Ordinary Shares?
The ticker symbol for Mainz Biomed N.V. - Ordinary Shares is MYNZ on the Nasdaq Stock Market
What is the current price of Mainz Biomed N.V. - Ordinary Shares?
The current price of Mainz Biomed N.V. - Ordinary Shares is 0.6183
When was Mainz Biomed N.V. - Ordinary Shares last traded?
The last trade of Mainz Biomed N.V. - Ordinary Shares was at 02/20/26 09:34 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.